Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Queensland Health
UBS
Mallinckrodt
Medtronic
McKesson
AstraZeneca
Merck
Federal Trade Commission
Colorcon

Generated: May 24, 2018

DrugPatentWatch Database Preview

AMARYL Drug Profile

or, see our see our flat-rate plans

« Back to Dashboard

Which patents cover Amaryl, and what generic alternatives are available?

Amaryl is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in AMARYL is glimepiride. There are fifteen drug master file entries for this compound. Forty-four suppliers are listed for this compound. Additional details are available on the glimepiride profile page.
Drug patent expirations by year for AMARYL
Pharmacology for AMARYL
Ingredient-typeSulfonylurea Compounds
Drug ClassSulfonylurea
Synonyms for AMARYL
1-((p-(2-(3-Ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)ethyl)phenyl)sulfonyl)-3-(trans-4-methylcyclohexyl)urea
1-[[4-[2-[[(3-Ethyl-4-methyl-2-oxo-2,3-dihydro-1H-pyrrol-1-yl)carbonyl]amino]ethyl]phenyl]sulphonyl]-3-(cis-4-methylcyclohexyl)urea (cis-Glimepiride)
1-[[P-[2-(3-ETHYL-4-METHYL-2-OXO-3-PYRROLINE-1-CARBOXAMIDO)ETHYL]PHENYL]SULFONYL]-3-(TRANS-4-METHYLCYCLOHEXYL)UREA
1-{[4-(2-{[(3-ethyl-4-methyl-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)carbonyl]amino}ethyl)phenyl]sulfonyl}-3-(trans-4-methylcyclohexyl)urea
1H-Pyrrole-1-carboxamide, 2,5-dihydro-3-ethyl-4-methyl-N-(2-(4-(((((4-methylcyclohexyl)amino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-oxo-, trans-
1H-Pyrrole-1-carboxamide, 3-ethyl-2,5-dihydro-4-methyl-N-(2-(4-(((((4-methylcyclohexyl)amino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-oxo-, trans-
24T6XIR2MZ
3-ETHYL-2,5-DIHYDRO-4-METHYL-N-[2-[4-[[[(TRANS-4-METHYLCYCLO-HEXYL)AMINO]CARBONYL]AMINO]SULFONYL]PHENYL]ETHYL-2-OXO-1H-PYRROLE-1-CARBOXAMIDE
3-Ethyl-2,5-dihydro-4-methyl-N-[2-[4-[[[[(trans-4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo-1H-pyrrole-1-carboxamide
3-ethyl-4-methyl-2-oxo-N-(2-{4-[({[(1r,4r)-4-methylcyclohexyl]carbamoyl}amino)sulfonyl]phenyl}ethyl)-2,5-dihydro-1H-pyrrole-1-carboxamide
3-ethyl-4-methyl-N-(4-(N-(((1r,4r)-4-methylcyclohexyl)carbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide
3-ethyl-4-methyl-n-(4-(n-((1r,4r)-4-methylcyclohexylcarbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro
3-ETHYL-4-METHYL-N-(4-(N-((1R,4R)-4-METHYLCYCLOHEXYLCARBAMOYL)SULFAMOYL)PHENETHYL)-2-OXO-2,5-DIHYDRO-1H-PYRROLE-1-CARBOXAMIDE
3-ethyl-4-methyl-N-(4-(N-((4-methylcyclohexyl)carbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide
3-ethyl-4-methyl-N-(4-(N-((trans-4-methylcyclohexyl)carbamoyl)sulfamoyl)phenethyl)-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide
3-ETHYL-4-METHYL-N-[2-(4-[[(TRANS-4-METHYLCYCLOHEXYL)CARBAMOYL]SULFAMOYL]PHENYL)ETHYL]-2-OXO-2,5-DIHYDRO-1H-PYRROLE-1-CARBOXAMIDE
3-ethyl-4-methyl-N-[2-(4-{[(4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide
3-Ethyl-4-Methyl-N-[2-(4-{[(Cis-4-Methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-Oxo-2,5-Dihydro-1h-Pyrrole-1-Carboxamide
3-ethyl-4-methyl-N-[2-(4-{[(trans-4-methylcyclohexyl)carbamoyl]sulfamoyl}phenyl)ethyl]-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide
3-ethyl-4-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-2-oxo-5H-pyrrole-1-carboxamide
3-ETHYL-4-METHYL-N-[2-[4-[(TRANS-4-METHYLCYCLOHEXYL) CARBAMOYLSULFAMOYL]PHENYL]ETHYL]-2-OXO-5H-PYRROL-1-CARBOXAMIDE
3-Ethyl-4-methyl-N-[2-[4-[[3-(4-methylcyclohexyl)ureido]sulfonyl]phenyl]ethyl]-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide
3-ethyl-4-methyl-N-{2-[4-({[(4-methylcyclohexyl)carbamoyl]amino}sulfonyl)phenyl]ethyl}-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide
4-ethyl-3-methyl-N-[2-[4-[(4-methylcyclohexyl)carbamoylsulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide
46931-EP2269989A1
46931-EP2270011A1
46931-EP2272825A2
46931-EP2272841A1
46931-EP2275414A1
46931-EP2287165A2
46931-EP2287166A2
46931-EP2292620A2
46931-EP2295406A1
46931-EP2295422A2
46931-EP2298769A1
46931-EP2298772A1
46931-EP2298776A1
46931-EP2301936A1
46931-EP2305648A1
46931-EP2308839A1
46931-EP2308847A1
46931-EP2308878A2
46931-EP2311822A1
479G971
64598P
684286-46-2
6KY687524K
93479-97-1
AB00513874
AB00513874_10
AB00513874_11
AB00513874-06
AB00513874-08
AB00513874-09
AB0073063
AB07644
AC-476
AC1L1G0T
AKOS015894919
AKOS015969663
Amarel
Amary
Amaryl (TN)
Amaryl, Glista OD, Glimepiride
AN-1036
AOB5663
AT-6093
BC204710
BCP9000728
Bio-0049
BPBio1_000751
BRD-K34776109-001-03-4
BRD-K42693031-001-01-8
BRN 5365754
BSPBio_000681
C07669
CAS-93479-97-1
CCG-101156
CCRIS 7083
CHEBI:5383
CHEBI:92609
CHEMBL1481
CHEMBL149223
cis-3-Ethyl-2,5-dihydro-4-methyl-N-[2-[4-[[[[(cis-4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo-1H-pyrrole-1-carboxamide
cis-Glimepiride
CPD000466368
CS-1844
CTK8E7555
D00593
D0B2GI
DB00222
diameprid
DR003022
DSSTox_CID_20675
DSSTox_GSID_40675
DSSTox_RID_79534
DTXSID5040675
Endial
FT-0626713
FT-0668978
FT-0696605
G0395
gimepiride
Glemax
glimax
Glimepirid
Glimepirida
Glimepirida [Spanish]
glimepiride
Glimepiride (JAN/USP/INN)
Glimepiride (JP17/USP/INN)
Glimepiride [USAN:BAN:INN]
Glimepiride [USAN:USP:INN:BAN]
Glimepiride EP Impurity A
Glimepiride for system suitability, European Pharmacopoeia (EP) Reference Standard
Glimepiride Impurity A
Glimepiride, >=98% (HPLC), solid
Glimepiride, cis-
Glimepiride, European Pharmacopoeia (EP) Reference Standard
Glimepiride, United States Pharmacopeia (USP) Reference Standard
Glimepiridum
Glimepiridum [Latin]
Glimepride
Glimer
GLIMPERIDE
glirid
Glista OD
Glorion
Glymepirid
GTPL6820
HE379567
HE417623
HMS1570C03
HMS2052L03
HMS2090K18
HMS2097C03
HMS2235L07
HMS3269A09
HMS3372O07
HMS3394L03
HMS3654F17
HOE 490
Hoe-490
HOE490
HY-B0104
I06-0029
KS-5238
LS-136752
MFCD00878417
MLS000759495
MLS001076674
MLS001401419
MLS003915622
MLS006011260
MolPort-003-847-587
MolPort-003-987-461
N-[4-[2-(3-ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)-ethyl]-benzenesulfonyl]-N'-4-methylcyclohexylurea
N'-{[4-(2-{[(3-ethyl-4-methyl-2-oxo-2,5-dihydro-1H-pyrrol-1-yl)carbonyl]amino}ethyl)phenyl]sulfonyl}-N-(4-methylcyclohexyl)carbamimidic acid
NC00406
NCGC00016960-01
NCGC00016960-02
NCGC00016960-03
NCGC00016960-04
NCGC00016960-05
NCGC00016960-07
NCGC00161404-01
NCGC00161404-02
NCGC00181757-01
Novo-glimepiride
NSC-759809
NSC759809
Oprea1_382896
Pharmakon1600-01504915
PMS-glimepiride
Prestwick0_000651
Prestwick1_000651
Prestwick2_000651
Prestwick3_000651
Q-201158
Ratio-glimepiride
Roname
s1344
SAM001246710
Sandoz glimepiride
SC-13775
SC-46287
SCHEMBL14371714
SCHEMBL14965363
SCHEMBL16084
SCHEMBL16086
SCHEMBL8738802
SMR000466368
SMR001550123
Solosa
SPBio_002602
SR-05000001508
SR-05000001508-3
STL451059
STL453194
Sugral
TL8005924
Tox21_110713
Tox21_110713_1
trans-1-(4-(2-(3-ethyl-4-Me-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamido)ethyl)phenylsulfonyl)-3-(4-methylcyclohexyl)urea
TRANS-1-(4-(2-(3-ETHYL-4-METHYL-2-OXO-2,5-DIHYDRO-1H-PYRROLE-1-CARBOXAMIDO)ETHYL)PHENYLSULFONYL)-3-(4-METHYLCYCLOHEXYL)UREA
trans-3-Ethyl-2,5-dihydro-4-methyl-N-[2-[4-[[[[(4-methyl cyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo-1H-pyrrole-1-carboxamide
Trans-3-Ethyl-2,5-dihydro-4-methyl-N-[2-[4-[[[[(4-methylcyclohexyl)amino]carbonyl]amino]sulfonyl]phenyl]ethyl]-2-oxo-1H-pyrrole-1-carboxamide
TX-017626
UNII-24T6XIR2MZ
UNII-6KY687524K
Vitaimin E
WIGIZIANZCJQQY-RUCARUNLSA-N
WIGIZIANZCJQQY-UHFFFAOYSA-N
ZINC100001976
ZINC100070954
ZINC537791

US Patents and Regulatory Information for AMARYL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us AMARYL glimepiride TABLET;ORAL 020496-001 Nov 30, 1995 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us AMARYL glimepiride TABLET;ORAL 020496-002 Nov 30, 1995 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us AMARYL glimepiride TABLET;ORAL 020496-003 Nov 30, 1995 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for AMARYL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us AMARYL glimepiride TABLET;ORAL 020496-003 Nov 30, 1995 ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us AMARYL glimepiride TABLET;ORAL 020496-001 Nov 30, 1995 ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us AMARYL glimepiride TABLET;ORAL 020496-002 Nov 30, 1995 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
McKesson
Daiichi Sankyo
Colorcon
Cipla
Healthtrust
Federal Trade Commission
Covington
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.